PEG-MGF

What PEG-MGF does

PEG-MGF adds polyethylene glycol to an MGF-related peptide, aiming to slow its breakdown. People use it for muscle growth and recovery. No human dose, benefit or half-life has been established. Most cited experiments tested different MGF constructs, and FDA flags possible immune reactions and impurities.

• People report using it for muscle growth; no controlled human study has shown a benefit. (Reported by users)
• A few users report muscles looking fuller or more pumped after injecting. (Reported by users)
• People also report using it for injury or workout recovery, which has not been shown in humans. (Reported by users)

Uses in the sources

• People report use for muscle growth; no controlled human benefit has been demonstrated. (Reported by users) (source)
• People discuss injury or workout recovery; animal MGF findings cannot establish human benefit. (Reported by users) (source)

PEG-MGF dosage

Typical reported dose: 200 mcg twice a week

• 200 mcg twice weekly: 200 mcg per injection wednesday and Saturday, under the skin. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 300–400 mcg on training days: Up to 300 mcg/day, sometimes 400 mcg/day on training days, sometimes on consecutive days, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 120 mcg after training: 120 mcg per reported injection after workouts; days per week not stated, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 200–400 mcg, 2–3 times weekly: 200–400 mcg per injection 2–3 times per week, under the skin. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• 1,000 mcg twice weekly: 1,000 mcg per session, divided into twenty 50 mcg injections twice weekly, with the second session about 3–4 days later, into muscle. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)
• Nasal experiment, 200 mcg twice daily: 200 mcg per administration, 400 mcg/day total twice daily, nasal spray. Reported by users, rare report. Studied in: Adults discussing physique or recovery use online. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix PEG-MGF

Comes as: Powder vial for mixing; community reports., Homemade nasal spray; one proposed experiment..

Mixed with: Community posts describe bacteriostatic water. Compatibility and stability are not established..

Common vial sizes: 2, 4 mg. Common water amounts: 2 mL.

• Vial sizes and water volumes are examples in posts, not a measured market distribution.
• No approved mixing instructions or beyond-use date exists for these reported products.
• Bacteriostatic water does not sterilize contaminated powder.
• The direct mixing log used 4 mg with 2 mL. Do not copy the incorrect syringe-unit rules in some replies.

Before mixing: No validated product-specific temperature, shelf life or shipping-stability data were found.

After mixing: No validated storage temperature or usable lifetime after mixing was found. Clear appearance does not prove sterility.

PEG-MGF side effects and risks

Reported side effects

• Injection-site pain, bruising or bleeding: No compound specific human rate. These are injection route risks., moderate. Persistent pain, a growing lump or bleeding needs assessment. (source)
• Infection or tissue injury from an unregulated injection: No MGF specific rate or denominator was found., serious. Spreading redness, fever or severe pain needs urgent assessment. (source)
• Allergic or immune reaction: FDA flags possible immune reactions to PEG MGF; no human rate is available., serious. Breathing trouble, swelling or fainting requires emergency care. (source)
• Blood-sugar changes, theoretical: No direct human evidence for this peptide. Risk is extrapolated from the wider hormone drug setting., serious. Check glucose with symptoms, particularly with insulin or glucose-lowering pills. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, fainting or widespread hives after exposure: Stop exposure and call emergency services immediately. Use prescribed emergency allergy treatment if available.
• Confusion, seizure, unconsciousness or low blood sugar that does not resolve: Get emergency care. Do not give food or drink to someone who cannot swallow safely.
• Hot, spreading injection-site redness, fever, pus or rapidly worsening pain: Stop injections and seek urgent medical assessment for infection or tissue injury.
• Chest pain, severe breathlessness, collapse or new neurological symptoms: Call emergency services now. Tell the team about all peptides and other drugs used.
• Severe muscle pain or swelling with numbness after a muscle injection: Seek emergency care for possible bleeding or pressure injury in the muscle.

Who should avoid it

• under18: Precaution: no pediatric dosing or safety study of this synthetic peptide was found.
• pregnant: Precaution: pregnancy and fetal safety have not been studied.
• breastfeeding: Precaution: breast-milk transfer and infant effects are unknown.
• tryingToConceive: Precaution: fertility effects and a safe time to stop before conception are unknown.
• activeCancer: Precaution: related MGF peptide promoted prostate cancer-cell growth. Whether PEG-MGF shares this effect is unknown.
• cancerHistory: Review prior cancer with the treating clinician. A laboratory cell-growth signal exists; human recurrence risk is unknown.
• diabetes: Blood-sugar effects are uncharacterized. Insulin and some diabetes pills already raise low-sugar risk.
• heartCondition: Animal heart findings do not establish human safety. New swelling or breathlessness needs assessment.
• kidneyDisease: Clearance in kidney disease is unknown. Kidney problems also change blood-sugar and bleeding risks.
• liverDisease: No dosing adjustment is established. Liver disease can complicate interpretation of IGF-1 tests and bleeding risk.
• bleedingDisorder: Muscle injections can cause bleeding or a deep collection of blood. This is a route risk, not a proven peptide effect.
• testedAthlete: WADA 2026 prohibits mechano growth factors at all times under S2.3. PEG modification does not make an analogue permitted.
• other: Avoid a substance that previously caused a serious allergic reaction. Actual vial ingredients may be uncertain.
• other: Avoid a PEG-containing product after confirmed PEG allergy. Product identity and the PEG component may be poorly characterized.

Interactions

• Insulin: Insulin causes low blood sugar. Any added effect of this peptide is untested; symptoms need a glucose check.
• Sulfonylureas and meglitinides: These pills can cause low blood sugar. No interaction study with MGF or PEG-MGF establishes a safe combination.
• Growth hormone, IGF-1 and GH-releasing drugs: Stacking adds untested growth and metabolic exposures. Human safety and claims about optimal spacing are unproven.
• Anticoagulants and antiplatelet drugs: Muscle punctures can bleed or bruise more on these drugs. A direct chemical interaction with the peptide is unknown.
• Unpegylated MGF: Related products may be duplicated in a stack. No human study establishes combined exposure or benefit.

Product quality risks

• No independent market survey of PEG-MGF purity, dose, sterility or endotoxin was found.
• Related MGF products have contained modified peptide or protein constructs. These findings do not establish what is in a PEG-MGF vial.
• Unregulated vials may have the wrong identity or amount, impurities, microbes or bacterial toxins. No compound-specific contamination rate is established.
• FDA flags possible immune reactions, peptide impurities and difficulty characterizing PEG-MGF. A claimed purity percentage cannot resolve these issues.

What to expect

No direct human study. Listed experiments concern related MGF fragments or PEG carrier systems, not characterized PEG-MGF.

Key studies

• MGF fragments, not PEG-MGF: negative replication: MGF fragments did not reproduce the muscle-cell effects reported in earlier work. (source)
• MGF in PEG hydrogel after a heart attack: MGF released from hydrogel rods preserved heart function; this was not PEG-MGF. (source)

PEG-MGF FAQ

• Is PEG-MGF FDA-approved? No approved product or indication found. FDA plans a PEG-MGF PCAC review by February 2027; no completed vote was found.
• How do people take it? Under the skin, wednesday and Saturday. Source: reported by users, not an established dose.
• What's the difference between PEG-MGF and IGF-1 LR3? PEG-MGF: a modified MGF peptide with no human dosing studies and uncertain identity in unregulated vials. IGF-1 LR3: an unapproved growth signal with no human trials found. Why people pair them: users alternate growth-factor products, hoping to separate cell growth from maturation.
• Can I take it with IGF-1 LR3? Users alternate growth-factor products, hoping to separate cell growth from maturation. No human combination study was found. Added harms and effective exposure are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). MGFs are named. S2 also covers substances with similar structure or effects, including PEGylated analogues.
• How long does a mixed vial last? No validated storage temperature or usable lifetime after mixing was found. Clear appearance does not prove sterility.